Last reviewed · How we verify
Wilson's disease — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Syprine | TRIENTINE | Bausch Health | Copper Chelator | Carbonic anhydrase 14 | 1985-01-01 | |
| Galzin | ZINC ACETATE | Eton | zinc acetate | 1980-01-01 | ||
| Cuprimine | PENICILLAMINE | Valeant Pharms Intl | Antirheumatic Agent [EPC] | 1970-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Bausch Health · 1 drug in Wilson's disease
- Eton · 1 drug in Wilson's disease
- Valeant Pharms Intl · 1 drug in Wilson's disease
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Wilson's disease:
- Wilson's disease treatment updates — RSS
- Wilson's disease treatment updates — Atom
- Wilson's disease treatment updates — JSON
Cite this brief
Drug Landscape (2026). Wilson's disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/wilson-s-disease. Accessed 2026-06-10.
Related
- Wilson's disease full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing